Pattaragarn Anirut, Sumboonnanonda Achra, Parichatikanond Paisal, Supavekin Suroj, Suntornpoch Vibul, Vongjirad Arun
Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand.
J Med Assoc Thai. 2005 Nov;88 Suppl 8:S232-41.
To define the patterns of clinicopathologic findings and to identify the risk factors for renal failure and mortality of childhood-onset systemic lupus erythematosus (SLE) in Thailand.
The study is a retrospective analysis of clinical manifestations, laboratory data, and pathologic findings, treatment modalities, and outcome of 82 patients with biopsy-proven lupus nephritis (LN) with disease onset between I January 1987 and 31 December 1997. All children developed these first manifestations at the age 13 years or under
Sixty-four (789%) patients were females and eighteen (22%) were males (ratio female/male = 3.5:1). The patients were followed for a mean period of 53.6 months (range 1 -141). The mean age at disease onset was 9.2 years (range 2-12.6). Class-IV LN, observed in 40 (48.8%) patients, was the most frequent histopathology on initial renal biopsy. Less frequent findings were class-II (30.5%), V (14.6%), I (3.7%) and III (2.4%) LN. Based on the renal histopathology and clinical presentations, patients were treated with corticosteroids alone or in combination with azathioprine or with intravenous cyclophosphamide (CYC). Methylprednisolone pulses were given in patients with clinically more severe disease. Follow-up biopsies, performed in 12 patients, showed no change in 4 patients, and were progressive in 8 patients. On final clinical evaluation, 20 patients died, 65% died from serious infections, 15% from cardiopulmonary complications, and 10% from end stage renal disease. As the whole group, survival rates were 89% and 74% at 12 and 60 months, respectively. The 5-year patient survival in class-II, class-IV and class- VLN patients were 83%, 67% and 64%, respectively. Within the group of class-IV LN, the 5-year survival in the patients treated with intravenous CYC was significantly better than those receiving prednisolone with or without azathioprine. Five-year kidney survival rates from the time of diagnosis to the endpoints of terminal renal failure were 94% for the whole group, and 100%, 96%, 91% in the class- V, class-II, and class-IV group, respectively. Initial presence of hypertension, hematuria, renal insufficiency were independent factors significantly associated with lower patient survival probabilities. There was no association of either patient and kidney survival with gender, age, cytopenia, and autoantibody level.
Infectious complications were the most common cause of morbidity and mortality in our pediatric patients with SLE. The immunosuppressive agents used to treat SLE seemed to be a major contribution to the patient survival. With judicious use of corticosteroid, intravenous CYC in severe SLE showed superior efficacy over oral prednisolone with or without azathioprine.
明确泰国儿童期起病的系统性红斑狼疮(SLE)的临床病理表现模式,并确定肾衰竭和死亡的危险因素。
本研究对1987年1月1日至1997年12月31日期间82例经活检证实为狼疮性肾炎(LN)且疾病起病的患者的临床表现、实验室数据、病理结果、治疗方式及预后进行回顾性分析。所有儿童在13岁及以下出现这些首发表现。
64例(78.9%)患者为女性,18例(22%)为男性(女性/男性比例 = 3.5:1)。患者平均随访53.6个月(范围1 - 141个月)。疾病起病时的平均年龄为9.2岁(范围2 - 12.6岁)。40例(48.8%)患者观察到IV级LN,是初次肾活检时最常见的组织病理学类型。较少见的表现为II级(30.5%)、V级(14.6%)、I级(3.7%)和III级(2.4%)LN。根据肾组织病理学和临床表现,患者单独使用糖皮质激素或联合硫唑嘌呤或静脉注射环磷酰胺(CYC)进行治疗。临床病情较重的患者给予甲泼尼龙冲击治疗。12例患者进行了随访活检,4例患者无变化,8例患者病情进展。在最终临床评估中,20例患者死亡,65%死于严重感染,15%死于心肺并发症,10%死于终末期肾病。作为整个组,12个月和60个月时的生存率分别为89%和74%。II级、IV级和V级LN患者的5年生存率分别为83%、67%和64%。在IV级LN组中,接受静脉注射CYC治疗的患者5年生存率显著高于接受泼尼松龙联合或不联合硫唑嘌呤治疗的患者。从诊断到终末期肾衰竭终点的5年肾脏生存率,整个组为94%,V级、II级和IV级组分别为100%、96%、91%。高血压、血尿、肾功能不全的初始存在是与较低患者生存概率显著相关的独立因素。患者和肾脏生存与性别、年龄、血细胞减少和自身抗体水平均无关联。
感染并发症是我们儿科SLE患者发病和死亡的最常见原因。用于治疗SLE的免疫抑制剂似乎是影响患者生存的主要因素。合理使用糖皮质激素时,严重SLE中静脉注射CYC显示出优于口服泼尼松龙联合或不联合硫唑嘌呤的疗效。